Le Lézard
Classified in: Health
Subject: SVY

Exactech Presented New Research Showcasing Its AI Technologies at the 2024 Orthopaedic Research Society Annual Meeting

GAINESVILLE, Fla., Feb. 22, 2024 /PRNewswire/ -- Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today it showcased 19 new knee, shoulder and ankle research studies highlighting the benefits of its Active Intelligence® technologies, Activit-Etm polyethylene and other products at the 2024 ORS Annual Meeting in California. Nineteen Exactech research studies in total were presented at the meeting.

Research on Exactech's Active Intelligence technologies evaluated the accuracy and precision of the tools, encompassing computer-assisted navigation, patient communication and more. One study about the use of computer-assisted surgical system for total ankle arthroplasty found that the use of navigation was associated with resection errors of less than 2mm and 2°.

Several new innovative shoulder studies are being presented which utilize machine learning to analyze CT image-based muscle features to analyze muscle size, shape, and quality and use these measurements to improve accuracy of shoulder arthroplasty outcomes predictions. Another important study was the first external validation for the Predict+® clinical decision support tool; this prospective study of 243 patients demonstrated that the accuracy associated with the external validation was similar or better than that of the internal validation.

"Exactech's focus on clinical outcomes research, along with our unique machine learning capabilities, have led to several discoveries that will inform development of future software tools while also contributing new clinical knowledge that can help surgeons treat their patients more effectively," said Chris Roche, Senior Vice President, Extremities. "I'm especially proud of our team's computer vision work which is analyzing CT images in new ways and correlating those measurements to our clinical outcomes data, helping us to interpret the clinical relevance of the image findings."

New knee research assessed the company's ligament-driven knee technology, with one study showcasing the system's approach to characterize and illustrate the knee laxity signature and the other demonstrating the short learning curve associated with adoption of the Newton® balancing technique.

"A vast amount of research is being conducted on Exactech's large joint products and technologies," said Laurent Angibaud, Exactech Vice President of Development, Advanced Surgical Technologies. "I am pleased, in particular, to present these new studies around knee laxity, as it opens the door to further personalize joint replacement based on patient-specific inputs."

Research studies about Exactech's Activit-E polyethylene proved its delamination resistance and wear resistance to be superior compared to conventional polyethylene.

For more information, visit www.exac.com.

About Exactech
Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, X, Instagram, YouTube and Vumedi. With Exactech by your side, you've got EXACTLY what you need.

SOURCE Exactech, Inc

These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

News published on and distributed by: